Maat Pharma SA
PAR:MAAT
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
6.48
9.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MAAT stock under the Base Case scenario is 7.9 EUR. Compared to the current market price of 7.78 EUR, Maat Pharma SA is Undervalued by 1%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Maat Pharma SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MAAT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Maat Pharma SA
Balance Sheet Decomposition
Maat Pharma SA
Current Assets | 40.6m |
Cash & Short-Term Investments | 32.1m |
Receivables | 7.1m |
Other Current Assets | 1.5m |
Non-Current Assets | 10.3m |
Long-Term Investments | 200k |
PP&E | 8.5m |
Intangibles | 1.3m |
Other Non-Current Assets | 238k |
Current Liabilities | 14.7m |
Accounts Payable | 5.7m |
Accrued Liabilities | 1.6m |
Other Current Liabilities | 7.4m |
Non-Current Liabilities | 10.6m |
Long-Term Debt | 10.1m |
Other Non-Current Liabilities | 527k |
Earnings Waterfall
Maat Pharma SA
Revenue
|
2.6m
EUR
|
Cost of Revenue
|
-826k
EUR
|
Gross Profit
|
1.7m
EUR
|
Operating Expenses
|
-25.9m
EUR
|
Operating Income
|
-24.2m
EUR
|
Other Expenses
|
27k
EUR
|
Net Income
|
-24.1m
EUR
|
Free Cash Flow Analysis
Maat Pharma SA
EUR | |
Free Cash Flow | EUR |
MAAT Profitability Score
Profitability Due Diligence
Maat Pharma SA's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Maat Pharma SA's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
MAAT Solvency Score
Solvency Due Diligence
Maat Pharma SA's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
Maat Pharma SA's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MAAT Price Targets Summary
Maat Pharma SA
According to Wall Street analysts, the average 1-year price target for MAAT is 15.3 EUR with a low forecast of 13.94 EUR and a high forecast of 16.8 EUR.
Dividends
Current shareholder yield for MAAT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
MAAT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 43 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.
Contact
IPO
Employees
Officers
The intrinsic value of one MAAT stock under the Base Case scenario is 7.9 EUR.
Compared to the current market price of 7.78 EUR, Maat Pharma SA is Undervalued by 1%.